Zobrazeno 1 - 10
of 155
pro vyhledávání: '"Delia Mezzanzanica"'
Autor:
Luca Forlani, Loris De Cecco, Vittorio Simeon, Biagio Paolini, Marina Bagnoli, Sabrina Chiara Cecere, Anna Spina, Eleonora Citeroni, Eliana Bignotti, Domenica Lorusso, Laura Arenare, Daniela Russo, Carmine De Angelis, Laura Ardighieri, Giosuè Scognamiglio, Michele Del Sesto, Germana Tognon, Daniela Califano, Clorinda Schettino, Paolo Chiodini, Francesco Perrone, Delia Mezzanzanica, Sandro Pignata, Antonella Tomassetti
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-17 (2023)
Abstract Background Validated prognostic biomarkers for anti-angiogenic therapy using the anti-VEGF antibody Bevacizumab in ovarian cancer (OC) patients are still an unmet clinical need. The EGFR can contribute to cancer-associated biological mechani
Externí odkaz:
https://doaj.org/article/218fe5829cc64926a70c90f947c39308
The deubiquitinase USP8 regulates ovarian cancer cell response to cisplatin by suppressing apoptosis
Autor:
Cristina Corno, Padraig D’Arcy, Marina Bagnoli, Biagio Paolini, Matteo Costantino, Nives Carenini, Elisabetta Corna, Paola Alberti, Delia Mezzanzanica, Diego Colombo, Stig Linder, Noemi Arrighetti, Paola Perego
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 10 (2022)
The identification of therapeutic approaches to improve response to platinum-based therapies is an urgent need for ovarian carcinoma. Deubiquitinases are a large family of ubiquitin proteases implicated in a variety of cellular functions and may cont
Externí odkaz:
https://doaj.org/article/8fd3870d67564c868a440ef7473efdf5
Autor:
Marina Bagnoli, Roberta Nicoletti, Monica Valitutti, Andrea Rizzo, Alessandra Napoli, Rafaela Montalvão De Azevedo, Antonella Tomassetti, Delia Mezzanzanica
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Epithelial ovarian cancer (EOC) remains the most lethal gynecological cancer and development of chemo-resistance is a major factor in disease relapse. Homologous recombination (HR) is a critical pathway for DNA double strand break repair and its defi
Externí odkaz:
https://doaj.org/article/4803c9df65ad40f0932e2028409870de
Autor:
Andrea Rizzo, Alessandro Satta, Giulia Garrone, Adalberto Cavalleri, Alessandra Napoli, Francesco Raspagliesi, Mariangela Figini, Loris De Cecco, Egidio Iorio, Antonella Tomassetti, Delia Mezzanzanica, Marina Bagnoli
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-13 (2021)
Abstract Background Choline kinase-α (ChoKα/CHKA) overexpression and hyper-activation sustain altered choline metabolism conferring the cholinic phenotype to epithelial ovarian cancer (OC), the most lethal gynecological tumor. We previously proved
Externí odkaz:
https://doaj.org/article/0f9fb6ba24d94872adce140b7a44398a
Autor:
Marina Fabbi, Delfina Costa, Daniela Russo, Laura Arenare, Gabriele Gaggero, Simona Signoriello, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Nunzia Simona Losito, Gilberto Filaci, Anna Spina, Daniela Califano, Giosuè Scognamiglio, Angiolo Gadducci, Delia Mezzanzanica, Marina Bagnoli, Silvano Ferrini, Vincenzo Canzonieri, Paolo Chiodini, Francesco Perrone, Sandro Pignata
Publikováno v:
Diagnostics, Vol 12, Iss 9, p 2118 (2022)
To find prognostic factors for advanced ovarian cancer patients undergoing first-line therapy with carboplatin, paclitaxel and bevacizumab, we investigated the expression of a disintegrin and metalloprotease 17 (ADAM17) in cancer tissues. ADAM17 has
Externí odkaz:
https://doaj.org/article/3475ee8b2aad49adbddeb11eea2ac3be
Autor:
Katia Rea, Francesca Roggiani, Loris De Cecco, Francesco Raspagliesi, Maria Luisa Carcangiu, Joyce Nair-Menon, Marina Bagnoli, Ileana Bortolomai, Delia Mezzanzanica, Silvana Canevari, Antonis Kourtidis, Panos Z. Anastasiadis, Antonella Tomassetti
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 37, Iss 1, Pp 1-16 (2018)
Abstract Background The disruption of E-cadherin-mediated adhesion is considered an important driver of tumor progression. Nevertheless, numerous studies have demonstrated that E-cadherin promotes growth- or invasion-related signaling, contrary to th
Externí odkaz:
https://doaj.org/article/3f20583c2fcb42c78a0c672eaafc268a
Autor:
Alessandro Satta, Giulia Grazia, Francesco Caroli, Barbara Frigerio, Massimo Di Nicola, Francesco Raspagliesi, Delia Mezzanzanica, Nadia Zaffaroni, Alessandro Massimo Gianni, Andrea Anichini, Mariangela Figini
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
T-cell-based immunotherapy strategies have profoundly improved the clinical management of several solid tumors and hematological malignancies. A recently developed and promising immunotherapy approach is to redirect polyclonal MHC-unrestricted T lymp
Externí odkaz:
https://doaj.org/article/f64637329ecd4ce3a1e75b4bcc107985
Autor:
Frank Antony, Cecilia Deantonio, Diego Cotella, Maria Felicia Soluri, Olga Tarasiuk, Francesco Raspagliesi, Fulvio Adorni, Silvano Piazza, Yari Ciani, Claudio Santoro, Paolo Macor, Delia Mezzanzanica, Daniele Sblattero
Publikováno v:
OncoImmunology, Vol 8, Iss 9 (2019)
The identification of effective biomarkers for early diagnosis, prognosis, and response to treatments remains a challenge in ovarian cancer (OC) research. Here, we present an unbiased high-throughput approach to profile ascitic fluid autoantibodies i
Externí odkaz:
https://doaj.org/article/ef2e03f8dde64ed5ab7483a47ee9a12f
Publikováno v:
Cancers, Vol 13, Iss 7, p 1544 (2021)
Epithelial ovarian cancer (EOC) remains the second most common cause of gynecological cancer deaths. To improve patients’ outcomes, we still need reliable biomarkers of early relapse, of which external independent validation is a crucial process. O
Externí odkaz:
https://doaj.org/article/e79bec0265d54f3ea0892fc67eaa8758
Autor:
Daniela Califano, Daniela Russo, Giosuè Scognamiglio, Nunzia Simona Losito, Anna Spina, Anna Maria Bello, Anna Capiluongo, Francesca Galdiero, Rossella De Cecio, Simona Bevilacqua, Piera Gargiulo, Edoardo Marchesi, Silvana Canevari, Francesco Perrone, Gennaro Daniele, Loris De Cecco, Delia Mezzanzanica, Sandro Pignata
Publikováno v:
Cells, Vol 9, Iss 4, p 903 (2020)
Ovarian cancer is the most lethal gynecological cancer, and despite years of research, with the exception of a BRCA mutation driving the use of PARP inhibitors, no new prognostic/predictive biomarkers are clinically available. Improvement in biomarke
Externí odkaz:
https://doaj.org/article/29afca81d8a14706bda54d0a15d0fa26